Treating Stroke with Regenerative Protein GDF11
Dr. Mark Allen, MD, co-founder and CEO of Elevian, developer of therapies to treat age-related diseases like stroke and diabetes, discusses the drug candidate, recombinant growth differentiation factor 11 (rGDF11) with broad therapeutic benefits demonstrated in numerous animal studies. “Science” recognized GDF11 as a top scientific breakthrough calling it “the rejuvenation factor”.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Diabetes. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Diabetes and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Diabetes?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Dr. Mark Allen is the co-founder and chief executive officer at Elevian. Dr. Allen has a BS in Applied Physics from Columbia University and an MD from UCLA. During his medical training, he developed one of the first web-based clinical decision support systems to guide ER physicians to make the right patient care decisions. After clinical trials demonstrating significant improvements in healthcare quality and cost, Dr. Allen founded Corticon to bring this new technology to market. Under Dr. Allen’s leadership as CEO, Corticon became one of the leading commercial rules engine software products, powering automated decision-making in healthcare, insurance, banking, retail and manufacturing. When Corticon was acquired by Progress, Dr. Allen took roles as Chief Technologist and then General Manager. In early 2017, excited by the recent scientific progress in the longevity industry, Dr. Allen left Progress with a passion to extend healthy lifespan. He partnered with Elevian’s scientific co-founders at Harvard to develop their GDF11 technology into new drugs, recruiting and leading a team of leading scientists and drug development veterans.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
